Thyroid Cancer Pipeline Offers Promising New Options for Treatment | DelveInsight

New York, USA, May 02, 2022 (GLOBE NEWSWIRE) — Thyroid Cancer Pipeline Offers Promising New Options for Treatment | DelveInsight

Thyroid Cancer Pipeline involves 40+ key companies continuously working towards developing 40+ Thyroid Cancer treatment therapies, as per DelveInsight

DelveInsight’s ‘Thyroid Cancer Pipeline Insight 2022‘ report provides comprehensive global coverage of available, marketed, and pipeline Thyroid Cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Thyroid Cancer pipeline domain.

Key Takeaways from the Thyroid Cancer Pipeline Report

• DelveInsight’s Thyroid Cancer Pipeline report depicts a robust space with 40+ active players working to develop 40+ pipeline therapies for Thyroid Cancer treatment. 
• The leading Thyroid Cancer companies include Shanghai Henlius Biotech, AffyImmune Therapeutics, Inc., Taizhou Hanzhong biomedical co. LTD,  Bristol-Myers Squibb, Takeda Oncology, Merck Sharp & Dohme Corp., Genentech, Inc., VBL Therapeutics, Eli Lilly and Company,  Chia Tai Tianqing Pharmaceutical Group Co., Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Purple Biotech, Boston Pharmaceuticals, Xynomic Pharmaceuticals, Inc., Turning Point Therapeutics, Inc., Iovance Biotherapeutics, Inc., Hoffmann-La Roche, Hutchison Medipharma Limited, Theratechnologies, TransThera Sciences (Nanjing), Inc., Novartis Oncology, SOTIO Biotech AG, Ono Pharmaceutical, Debiopharm, Tmunity Therapeutics, Codiak BioSciences, Oncoceutics, GlobeImmune, C4 Therapeutics, Innovative Cellular Therapeutics, Applied Pharmaceutical, and others are developing novel drug candidates to improve the Thyroid Cancer treatment landscape.
• Key Thyroid Cancer pipeline therapies in various stages of development include HLX208, AIC100, HX008, Nivolumab, Ipilimumab, MLN0128, Pembrolizumab, Vemurafenib, VB-111, LOXO-260, Anlotinib hydrochloride, HA121-28, CM-24, BOS172738, XP-102, TPX-0046, LN 145, Alectinib, Surufatinib, TH1902, TT-00420, Spartalizumab, SO-C101, LY3410738, Binimetinib, DEBIO 1124, CDK-002, ONC201, GI 6207, APS03118, exoASO STAT6, and others.
• In April 2022, Molecular Targeting Technologies Inc. (MTTI) and ITM Isotope Technologies Munich SE (ITM) announced the signing of a global clinical supply agreement that provides MTTI with ITM’s medical radioisotope no-carrier-added lutetium-177 (n.c.a. 177Lu / EndolucinBeta®) for the preclinical and clinical development as well as potential commercial production of MTTI’s radiopharmaceutical candidate n.c.a. 177Lu-EBTATE to treat a range of cancers. N.c.a. 177Lu-EBTATE is currently in clinical development for the treatment of neuroendocrine tumors, a special form of thyroid cancer (Hürthle cell), and a rare type of head and neck cancer (nasopharyngeal cancer).
• In April 2022, Purple Biotech Ltd., announced favorable safety and efficacy data supporting the advancement of CM24, a first-in-class clinical-stage monoclonal antibody with the potential to treat multiple solid tumor cancers.
• In January 2022, Applied Pharmaceutical Science, Inc. announced the Investigational New Drug (IND) application for APS03118, a next-generation selective RET inhibitor, which has been approved by the U.S. Food and Drug Administration (FDA). The clinical application is also in the process of being submitted to the National Medical Products Administration (NMPA) in China, and a global multi-center clinical trial is in the pipeline for initiation in the second quarter of 2022 in the U.S., China, and Australia, etc.
• In May 2021, AffyImmune Therapeutics announced that the US Food and Drug Administration (FDA) granted Fast Track designation to its lead compound, AIC100, for the treatment of anaplastic thyroid cancer and refractory poorly differentiated thyroid cancer

Request a sample and discover the recent breakthroughs happening in the Thyroid Cancer pipeline landscape @ Thyroid Cancer Pipeline Outlook

The Thyroid Cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Thyroid Cancer products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Thyroid Cancer pipeline landscape.

Thyroid Cancer Overview

Thyroid cancer develops in the thyroid cells, which are located at the base of the neck, directly behind Adam’s apple. The thyroid gland secretes hormones that control the heart rate, blood pressure, body temperature, and weight. Thyroid cancer symptoms may not exhibit at first. However, the common symptoms of Thyroid Cancer include neck pain and swelling. The Thyroid Cancer causes are still not known. There are various types of thyroid cancer such as Papillary Thyroid Cancer, Medullary Thyroid Cancer, Anaplastic Thyroid Cancer, and others. Some grow slowly, while others might be quite aggressive.

Physical exams, blood tests, imaging tests, and genetic testing are among the common methods used for Thyroid Cancer diagnosis. The Thyroid Cancer treatment options include Thyroid Cancer surgery, radioactive iodine (Radioiodine) therapy, and thyroid hormone therapy.

Thyroid cancer survival rates are increasing. Some doctors believe this is because new technology is allowing them to detect tiny thyroid tumors that were previously undetected. Moreover, Thyroid Cancer screening tests are also being studied in clinical trials. 

Find out more about diagnosis and treatment of patients with Thyroid Cancer @ Thyroid Cancer Treatment

A snapshot of the Thyroid Cancer Pipeline Drugs mentioned in the report:

Learn more about the novel and emerging Thyroid Cancer pipeline therapies @ Thyroid Cancer Clinical Trials

Thyroid Cancer Therapeutics Assessment

The Thyroid Cancer Pipeline report proffers an integral view of the Thyroid Cancer emerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action, and Route of Administration.

Scope of the Thyroid Cancer Pipeline Report 

• Coverage: Global 
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Therapeutics Assessment By Route of Administration: Oral, Parenteral, Subcutaneous, Topical, Intravenous
• Therapeutics Assessment By Molecule Type: Gene therapy, Small molecule, Polymers, Peptides, Monoclonal antibodies
• Therapeutics Assessment By Mechanism of Action: Platelet-derived growth factor receptor antagonists; Raf kinase inhibitors, Receptor protein-tyrosine kinase antagonists, Vascular endothelial growth factor receptor antagonists, Fibroblast growth factor receptor antagonists,  Platelet-derived growth factor-beta receptor antagonists, Proto-oncogene protein c-kit inhibitors, Vascular endothelial growth factor receptor 3 antagonists, Vascular endothelial growth factor receptor-1 antagonists, Vascular endothelial growth factor receptor-2 antagonists, Antibody-dependent cell cytotoxicity, Programmed cell death-1 receptor antagonists, T lymphocyte stimulants, Proto oncogene protein b raf inhibitors, Immunologic cytotoxicity, T lymphocyte replacements
• Key Thyroid Cancer Companies: Shanghai Henlius Biotech, AffyImmune Therapeutics, Inc., Taizhou Hanzhong biomedical co. LTD,  Bristol-Myers Squibb, Takeda Oncology, Merck Sharp & Dohme Corp., Genentech, Inc., VBL Therapeutics, Eli Lilly and Company,  Chia Tai Tianqing Pharmaceutical Group Co., Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Purple Biotech, Boston Pharmaceuticals, Xynomic Pharmaceuticals, Inc., Turning Point Therapeutics, Inc., Iovance Biotherapeutics, Inc., Hoffmann-La Roche, Hutchison Medipharma Limited, Theratechnologies, TransThera Sciences (Nanjing), Inc., Novartis Oncology, SOTIO Biotech AG, Ono Pharmaceutical, Debiopharm, Tmunity Therapeutics, Codiak BioSciences, Oncoceutics, ,GlobeImmune, C4 Therapeutics, Innovative Cellular Therapeutics, Applied Pharmaceutical, and others
• Key Thyroid Cancer Pipeline Therapies: VB-111, LOXO-260, Anlotinib hydrochloride, HA121-28, CM-24, BOS172738, XP-102, TPX-0046, LN 145, Alectinib, Surufatinib, TH1902, TT-00420, Spartalizumab, SO-C101, LY3410738, Binimetinib, ,DEBIO 1124, CDK-002, ONC201, GI 6207, APS03118, and others.

Dive deep into rich insights into new Thyroid Cancer drugs, visit @ Thyroid Cancer Emerging Therapies 

Table of Contents

For further information on the Thyroid Cancer pipeline therapeutics, reach out @ Thyroid Cancer Targetted Therapy

Related Reports

Thyroid Cancer Epidemiology Forecast

Thyroid Cancer Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical, and forecasted Thyroid Cancer epidemiology in the 7MM.

Thyroid Cancer Market

Thyroid Cancer Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Thyroid Cancer companies such as Bristol-Myers Squibb, Genentech, AffyImmune Therapeutics, Inc., Taizhou Hanzhong biomedical co. LTD, among others.

Thyroid Hormone Receptor Agonists Pipeline

Thyroid Hormone Receptor Agonists Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Thyroid Hormone Receptor Agonists companies such as Terns Pharmaceuticals, Ascletis, Autobahn Therapeutics, among others.

Papillary Thyroid Cancer Pipeline

Papillary Thyroid Cancer Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Papillary Thyroid Cancer companies such as the University of Colorado, Assiut University, University Health Network, among others.

Medullary Thyroid Cancer Pipeline

Medullary Thyroid Cancer Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Medullary Thyroid Cancer companies such as the Eli Lilly, Exelixis, Columbia University, among others.

Anaplastic Thyroid Cancer Pipeline

Anaplastic Thyroid Cancer Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Anaplastic Thyroid Cancer companies such as the Novartis, AstraZeneca, Fujian Medical University, among others.

Other Trending Reports

Hepatitis A Market

“Hepatitis A Market” research report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Hepatitis A market size, share, and trends in 7MM. Some of the key companies in the Hepatitis A Therapeutics Market include Boryung Pharmaceutical, Cadila Healthcare, Indian Immunologicals, Biological E Limited, and others

Granulomatosis With Polyangiitis Market

“Granulomatosis With Polyangiitis Market” research report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Granulomatosis With Polyangiitis market size, share, and trends in the 7MM. The key companies in the Granulomatosis With Polyangiitis Therapeutics Market include InflaRx GmbH, Bristol-Myers Squibb, Hoffmann-La Roche, and others.

Atopic Dermatitis Market 

“Atopic Dermatitis Market” research report provides a detailed overview of the disease, historical and forecasted epidemiology as well as the Atopic Dermatitis market size, share, and trends in the 7MM. The key companies in the Atopic Dermatitis Therapeutics Market include Abbvie, Eli Lily, Galderma, Onenss Biotech, LEO Pharma, Arena Pharmaceuticals, AOBiome Therapeutics, Pfizer, and several others. 

Hypertrophic Scar Market

“Hypertrophic Scar Market” research report delivers an in-depth understanding of the Hypertrophic Scar, historical and forecasted epidemiology as well as the Hypertrophic Scar market size, share, and trends in the 7MM. The key companies in the Hypertrophic Scar Therapeutics Market include Henry Ford Health System, Gladerma, Phio Pharmaceuticals, and others.

Secondary Hyperparathyroidism Market

“Secondary Hyperparathyroidism Market” research report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Secondary Hyperparathyroidism market size, share, and trends in the 7MM. The key companies in the Hypertrophic Scar Therapeutics Market include Sanwa Kagaku Kenkyusho, OPKO Health, TaiRx, Amgen, and others.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect With Us at LinkedIn | Facebook | Twitter